James N. Lowder - Concepedia

Author

James N. Lowder

Also Known As

J LOWDER, J Lowder, J N Lowder, J. Lowder, J. N. Lowder, J.N. Lowder, JAMES N. LOWDER, James Lowder, James N LOWDER, James N Lowder

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Stanford University Astex Pharmaceuticals PDL BioPharma (United States)University of Chicago The University of Texas MD Anderson Cancer Center

About

James N. Lowder is an author at Stanford University specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	1.1K
2	Health Sciences	5	5	530
3	Allergy	2	2	30
4	Public Health	1	1	60
5	Cellular Therapies	1	1	38

James N. Lowder

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
A clinical trial of anti-idiotype therapy for B cell malignancy TC Meeker, James N. Lowder, DG Maloney, Blood	1985	423
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri, The Lancet Oncology Hematological MalignancyDose-escalation Phase 1OncologyMyelodysplastic SyndromeMixed-phenotype Acute Leukemia	2015	280
Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies T C Meeker, James N. Lowder, Michael L. Cleary, New England Journal of Medicine	1985	254
A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis Scott E. Plevy, Bruce Salzberg, Gert Van Assche, Gastroenterology InflammationAnti-inflammatoryAutoimmune DiseaseImmunologyGastroenterology	2007	144
Bacteremias and Fungemias in Oncologic Patients With Central Venous Catheters James N. Lowder Archives of Internal Medicine Intensive TherapyVenous DiseaseHealth SciencesCentral Venous CathetersHealthcare-associated Infection	1982	141
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, The Lancet Haematology Hematological MalignancyOral Fixed-dose CombinationPharmacologyHematologyPharmacotherapy	2019	119
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Ajjai Alva, Gregory A. Daniels, Michael K. Wong, Cancer Immunology Immunotherapy	2016	102
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis William J. Sandborn, J.‐F. COLOMBEL, Matthew Frankel, Gut	2010	87
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello, Clinical Cancer Research	2019	77
A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease Paul A. Carpenter, James N. Lowder, Laura Johnston, Biology of Blood and Marrow Transplantation	2005	76

Page 1